J&J Discusses Details of Proposed Actelion Deal

Jan 03, 2017


Late last week, Reuters reported that Johnson & Johnson was negotiating a deal to acquire Swiss biotech Actelion Ltd that would separate its commercialized portfolio from its R&D division, according to unnamed sources.

This could allow J&J to acquire Actelion with a cash offer of about $260 per share, which is a little more than it had offered earlier this month. It also would allow Actelion shareholders to benefit financially from Actelion's R&D pipeline, the story said. In addition, sources say the deal being discussed might involve Actelion's R&D pipeline to be placed in a new publicly traded company.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments